Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis.

Christen L VagtsYi-Shin ChangChristian Ascoli Jessica M LeeKai HuangYue HuangRuth A CherianNandini SarupSamantha R WarpechaRussell Edafetanure-IbehMd-Ruhul AminTasmin SultanaMahmood GhassemiNadera J SweissRichard NovakDavid L PerkinsPatricia W Finn

Published in: ERJ open research (2023)

Sarcoidosis subjects exhibit nAb induced by the BNT162b2 mRNA SARS-CoV-2 vaccine at levels comparable to controls that persists at 6 months indicating conferred immunity. Trimer IgG levels are poor predictors of nAb in subjects with sarcoidosis. Studies of further antibody immunoglobulins and subtypes warrant investigation.

Keyphrases

sars cov
advanced non small cell lung cancer
coronavirus disease
respiratory syndrome coronavirus
binding protein